

share
Bms-615 CAS NO 2180127-82-4
Unit Price:
CAS No.:2180127-82-4
Grade:Pharmacy Grade
Content:99.9%
Brand:Customizable
Packaging:Customizable
Description
Bms-615 is a high-purity, advanced pharmaceutical intermediate or active ingredient identified by CAS NO 2180127-82-4. This compound is critical for research and development in modern drug discovery programs, particularly in targeted therapeutic areas. It is primarily utilized by pharmaceutical companies, biotechnology research firms, and academic institutions engaged in the synthesis of novel bioactive molecules.
Application
- Pharmaceutical Intermediate: Key building block in the synthesis of novel drug candidates for preclinical and clinical research.
- Biochemical Research: Used as a reference standard or reagent in proteomics and enzyme inhibition studies.
- Drug Discovery: Serves as a core scaffold for medicinal chemistry optimization in hit-to-lead and lead optimization campaigns.
- Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for scale-up synthesis under cGMP conditions.
- Academic Research: Utilized in university laboratories for investigating new biological pathways and mechanisms of action.
Basic Information
| Product Name | Bms-615 |
| CAS No. | 2180127-82-4 |
| Molecular Formula | Contact for details |
| Molecular Weight | Contact for details |
| Synonyms | BMS-615; BMS 615; 2180127-82-4; Bms615; Bms 615; (Provide specific IUPAC name upon request) |
| EINECS | Contact for details |
Quality Control
Our Bms-615 is manufactured under strict quality management systems to ensure batch-to-batch consistency and high purity. Each lot is accompanied by a comprehensive Certificate of Analysis (COA) detailing identity, purity, and impurity profiles. We adhere to relevant industry guidelines to support our clients' regulatory and research requirements.
Storage
Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider using desiccants.
Specification
| Item | Specification |
|---|---|
| Appearance | White to off-white solid |
| Identification (IR) | Conforms to reference spectrum |
| Assay (HPLC) | ≥ 98.0% |
| Related Substances (HPLC) | Total impurities ≤ 2.0% |
| Water Content (KF) | ≤ 0.5% |
| Residue on Ignition | ≤ 0.1% |
Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.
Hot Related Products


Olaparib CAS NO 763113-22-0


Vorinostat CAS NO 149647-78-9


Midostaurin CAS NO 120685-11-2


4,4'-Diacetyldiphenylureabis(Guanylhydrazone)Ditosylate CAS NO 15427-93-7


Bendamustine CAS NO 16506-27-7


Oxazolopyridocarbazole CAS NO 103769-63-7


V CAS NO 103956-33-8


Regelin CAS NO 109974-21-2


Regopar CAS NO 110445-23-3


Paprin CAS NO 114949-43-8


2-Furyl-[4-[4-[[3-[2-Hydroxy-3-(Propan-2-Ylamino)Propoxy]Phenyl]Amino] -6,7-Dimethoxy-Quinazolin-2-Yl]Piperazin-1-Yl]Methanone Trihydrochlori De CAS NO 111218-84-9


2-Furyl-[4-[4-[[4-[2-Hydroxy-3-(Propan-2-Ylamino)Propoxy]Phenyl]Amino] -6,7-Dimethoxy-Quinazolin-2-Yl]Piperazin-1-Yl]Methanone Trihydrochlori De CAS NO 111218-85-0


Lestaurtinib CAS NO 111358-88-4


Ge500 CAS NO 118549-88-5


Ag 85-12 CAS NO 121521-00-4


Indifor CAS NO 124399-52-6


2-(4-Allyl-1-Piperazinyl)-4-(2-Methylpentoxy)Quinazoline Fumarate CAS NO 129664-18-2


2-(4-Allyl-1-Piperazinyl)-4-Hexyloxyquinazoline Fumarate CAS NO 129664-17-1


Tjn 505 CAS NO 131653-96-8


Gelevin CAS NO 135151-90-5
Why choose US
Trusted Manufacturer
With our own production facilities, we ensure consistent quality, reliable supply, and full traceability.
Rigorous Quality Assurance
Each batch undergoes strict QC, accompanied by COA, MSDS, and full compliance with international standards.
Advanced R&D Expertise
Our in-house lab drives process innovation, new product development, and tailored synthesis solutions.






